Lilly posts early Heart-2 data for one-time LDL gene editor
Bottom line
Eli Lilly reported new Phase 1b Heart-2 data showing that a single infusion of VERVE-102, an investigational in vivo base-editing therapy, reduced PCSK9 by up to 88% and LDL cholesterol by up to 62% in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease. The interim analysis included 35 participants across six dose cohorts, with LDL-C reductions sustained for as long as 18 months. Lilly said VERVE-102 was well tolerated, with no treatment-related serious adverse events or dose-limiting toxicities, and the data were presented at the European Atherosclerosis Society Congress and published May 25, 2026, in The New England Journal of Medicine. (investor.lilly.com)
Why it matters: While this is a human cardiometabolic study rather than a veterinary program, it signals how quickly one-time gene-editing approaches are moving toward mainstream chronic disease management. For veterinary professionals, the broader relevance is strategic: durable, single-course therapies are increasingly being tested for common lifelong conditions, and that could shape future expectations around translational medicine, specialty referral conversations, and how pet parents think about long-term disease control. The safety profile also matters because Verve’s earlier PCSK9 program, VERVE-101, had raised safety concerns, making Heart-2 an important reset for the platform. (statnews.com)
What to watch: Lilly said it plans to begin enrolling a Phase 2 study of VERVE-102 by the end of 2026. (investor.lilly.com)
Eli Lilly has posted early but closely watched clinical data for VERVE-102, a one-time gene-editing treatment aimed at lowering LDL cholesterol by permanently switching off the PCSK9 gene in the liver. In the ongoing Phase 1b Heart-2 trial, the therapy produced dose-dependent reductions in circulating PCSK9 and LDL-C, with the top reported cohort reaching an average 62% LDL-C reduction after a single intravenous infusion. Lilly presented the results at the European Atherosclerosis Society Congress and said the study was published May 25, 2026, in The New England Journal of Medicine. (investor.lilly.com)
The program has a longer backstory than the latest headline suggests. Verve Therapeutics began developing PCSK9-editing candidates as part of its strategy to turn validated cardiovascular targets into single-course therapies. In October 2023, Lilly expanded its relationship with Verve by acquiring key rights tied to Verve’s cardiovascular gene-editing programs targeting PCSK9 and ANGPTL3, adding commercial weight to the platform well before the current data readout. Lilly later acquired Verve outright in a roughly $1 billion deal, according to STAT, making Heart-2 an early test of whether that bet can translate into clinically meaningful and commercially relevant results. (globenewswire.com)
Heart-2 is an open-label, single-ascending-dose Phase 1b study in adults with heterozygous familial hypercholesterolemia or premature coronary artery disease who still need additional LDL lowering despite maximally tolerated oral therapy. In Lilly’s interim analysis of 35 participants, mean LDL-C reductions were 9% at 0.3 mg/kg, 44% at 0.45 mg/kg, 45% at 0.6 mg/kg, 33% at 0.7 mg/kg, 51% at 0.8 mg/kg, and 62% at 1.0 mg/kg. Mean PCSK9 reductions ranged from 51% to 88%, and Lilly said the effect has remained durable for up to 18 months of follow-up. The company also noted that all participants received the full planned dose and that no participant withdrew from the study. (investor.lilly.com)
Mechanistically, VERVE-102 uses an adenine base editor delivered in a GalNAc-lipid nanoparticle formulation to target liver cells and inactivate PCSK9. That matters because the field has been trying to show not just efficacy, but a delivery and safety profile that could support broader use in chronic cardiovascular disease. Lilly said VERVE-102 was well tolerated across dose levels, with no treatment-related serious adverse events and no dose-limiting toxicities; reported treatment-related adverse events were low-grade infusion reactions and fatigue. The FDA has also granted Fast Track designation for the candidate in patients with hyperlipidemia and high lifetime cardiovascular risk. (investor.lilly.com)
Outside observers see the data as encouraging, but still clearly early. STAT described the readout as an important test for whether a one-time treatment could eventually help patients who struggle to stay on chronic LDL-lowering therapy. Fierce Biotech noted that the LDL reductions now look broadly comparable to those seen with established PCSK9 inhibitors, and quoted William Blair analyst Myles Minter saying that maintaining LDL-C lowering above 50% with a good safety profile is roughly the threshold the field wants to see. Fierce also reported that Verve chief medical officer Scott Vafai said dosing is still ongoing, underscoring that the dose-selection story is not finished. (statnews.com)
Why it matters: For veterinary professionals, this is less about direct clinical application today and more about where biomedicine is heading. Companion animal medicine increasingly lives downstream of human innovation, especially in genetics, specialty therapeutics, and pet parent expectations. A credible one-time treatment model for a common chronic condition like hypercholesterolemia reinforces a wider shift away from repeated dosing and toward durable genomic interventions. Even if veterinary use remains distant, these programs can influence investor behavior, translational research priorities, and how specialty clinicians frame the future of inherited and lifelong disease management. The case is also a reminder that safety still defines the field: Heart-2’s clean early profile carries extra weight because Verve’s earlier PCSK9 candidate encountered safety issues, so clinicians and industry watchers will likely focus as much on tolerability and durability as on headline LDL numbers. (statnews.com)
There are still obvious unanswered questions. The trial remains small, open-label, and early stage, and the eventual target population may prove narrower than the broad promise of “one-time treatment” suggests. As Fierce Biotech noted, the risk-benefit equation may look very different for a younger patient with inherited severe LDL elevation than for an older patient with more conventional hypercholesterolemia. Long-term follow-up will matter, particularly for a permanent editing approach, as will manufacturing, pricing, and payer acceptance if the program advances. (fiercebiotech.com)
What to watch: Lilly said it plans to start Phase 2 enrollment by the end of 2026, making dose selection, longer-term safety follow-up, and clarity on the intended patient population the next major milestones. (investor.lilly.com)